HOW TO WRITE THE RESULTS SECTION

Slides:



Advertisements
Similar presentations
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Advertisements

Clinical research original article: How to write an article and get it published in European Urology Shahrokh F. Shariat, MD Chair and Professor, Medical.
Departments of Medicine and Biostatistics
Edward P. Sloan, MD, MPH, FACEP Manuscript Writing: How to Get your Manuscript Written Effectively and Easily.
Writing Result DR. JAWAHER. General role present your key, without interpretation, in an orderly and logical sequence using both illustrative materials.
EVIDENCE BASED MEDICINE
Steven Joniau Filip Ameye
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
How to Write a Scientific Paper Hann-Chorng Kuo Department of Urology Buddhist Tzu Chi General Hospital.
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
Howard M. Sandler, MD University of Michigan Medical School
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
Systematic Reviews.
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
DISCUSSION AND CONCLUSION Alberto Briganti Urological Research Institute Vita Salute San Raffaele University Dept. of Urology, Milan, Italy.
Clinical Research Original Article: The Editor’s tricks Shahrokh F. Shariat, M.D. Associate Professor of Urology and Medical Oncology Director, Bladder.
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
How to write a scientific article Nikolaos P. Polyzos M.D. PhD.
on behalf of the ACOSOG Z4032 Investigators
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
BY DR. HAMZA ABDULGHANI MBBS,DPHC,ABFM,FRCGP (UK), Diploma MedED(UK) Associate Professor DEPT. OF MEDICAL EDUCATION COLLEGE OF MEDICINE June 2012 Writing.
1 BLA Sipuleucel-T (APC-8015) FDA Statistical Review and Findings Bo-Guang Zhen, PhD Statistical Reviewer, OBE, CBER March 29, 2007 Cellular, Tissue.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
Source: S. Unchern,  Research is not been completed until the results have been published.  “You don’t write because you want to say something,
Presented By Shin Fujita at 2016 ASCO Annual Meeting
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in pre-menopausal.
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
CCO Independent Conference Highlights
WHAT THE EDITOR LOOKS FOR IN REVIEWING THE RESULTS AND DISCUSSION
Volume 62, Issue 3, Pages (September 2012)
Prognostic significance of tumor subtypes in male breast cancer:
R. Michelle Sarin, MD Mentor: Jeffrey Fowler, MD
A Systematic Review and Meta-analysis
Surgical Treatment in Locally Advanced Prostate Cancer
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
TBCRC (the translational breast cancer research consortium) 005 Prospective study
New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.
The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Urol Int 2017;99:
Prognosis of younger patients in non-small cell lung cancer
Prof.S.M.Haider Faisal Hameed Wahab Kadri
Critical Reading of Clinical Study Results
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
Prostate Cancer: Highlights from 2006
Research Rotation Part II
Apollo Gleneagles Hospitals,
Volume 378, Issue 9804, Pages (November 2011)
European Urology Oncology
Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.
What is New in Hormone Therapy for Prostate Cancer in 2007?
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Clinica urologica, università di Padova
Volume 375, Issue 9722, Pages (April 2010)
Patients who have received chemotherapy (n=60)
What the Editors want to see!
Disease-specific survival
PUT TITLE HERE Put Co-Author Listing Here
How To conduct a thesis 1- Define the problem
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
ENGAGe How to make a patient organization poster
How To conduct a thesis 1- Define the problem
Fernando P. Secin, Fernando J. Bianco, Nicholas T
JAMA Ophthalmology Journal Club Slides: Timing of Intervention in Congenital Nasolacrimal Duct Obstruction Sathiamoorthi S, Frank RD, Mohney BG. Spontaneous.
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Presenter: Göran Ahlgren, M.D., Ph.D. Dept of Urology,
Preparing an abstract for submission at a conference for presentation
Presentation transcript:

HOW TO WRITE THE RESULTS SECTION Stephen A. Boorjian, MD Carl Rosen Professor of Urology Vice Chair of Research Director, Urologic Oncology Fellowship Department of Urology Mayo Clinic, Rochester, MN

DISCLOSURES Financial: none Intellectual: “this is how I do it” Many approaches can be successful

KEY THEME Consider the same features in writing a paper as when reviewing

OUTLINE FOR TALK Writing the text of the Results section of the manuscript Tables/Figures What to include in the results section of the Abstract

WRITING THE RESULTS SECTION OF THE MANUSCRIPT KEY SECTION OF MANUSCRIPT “Non-fixable” with revisions “50,000-foot view”: broad specific First paragraph = overall number included/excluded in study If large number excluded – provide evidence that population excluded not significantly different than population included Exclude selection bias

WRITING THE RESULTS SECTION OF THE MANUSCRIPT First paragraph (continued): Cohort demographics i.e. median age, sex distribution CAVEAT – DO NOT RECAPITULATE IN THE TEXT WHAT IS IN TABLES Should provide one or two critical demographic details, and/or points not included in the tables

BROAD TO NARROW AT START, WITH COHORT DEMOGRAPHICS FIRST

WRITING THE RESULTS SECTION OF THE MANUSCRIPT After first paragraph, should move from broad to specific Demographics  treatment details  outcomes Critical that all relevant treatment details be included i.e. for manuscript on RP  number who received adjuvant therapy, number who received salvage therapy

REPORTING OF OUTCOMES IN THE TEXT OF THE RESULTS SECTION KEY: Report median follow-up in survivors, with interquartile range KEY: Report the number of specific events for each outcome measure of interest (recurrence, cancer death, all cause mortality) Not just percentages! i.e. don’t just say “The 5 year survival was 65% versus 42%...”

REPORTING OF OUTCOMES IN THE TEXT OF THE RESULTS SECTION “The median follow-up after surgery was 10.1 years (IQR 8.4, 12.2), during which time 780 patients experienced biochemical recurrence, 560 were diagnosed with clinical metastases, and 600 died, including 380 who died of prostate cancer.”

SECOND PARAGRAPH OF THE RESULTS: FOLLOW-UP AND EVENTS

REPORTING OF OUTCOMES IN THE TEXT OF THE RESULTS SECTION KEY: After reporting demographics, treatment, raw number of events, when reporting statistical analyses, move from univariable (Kaplan Meier) data first to multivariable model data second KEY: Make sure that every table/figure is referenced in the text (including supplemental) And vice versa – make sure that context is provided in the text for the data from every table/figure After reporting analyses from overall cohort, then report subgroup (sensitivity) analyses

WRITING THE RESULTS SECTION: A CHANCE FOR A DATA “CHECK POINT” As you are writing, make sure that the “story” you are telling makes sense i.e. are you reporting an association of a treatment with outcomes that demonstrates congruous findings with recurrence, cancer- specific mortality, and all-cause mortality? Do you see a dose-effect with treatment? If not, re-evaluate the data/analyses, and be prepared to explain discrepancies in Discussion

MAKING SURE THE DATA MAKES SENSE

RESULTS SECTION OF TEXT: WHAT NOT TO INCLUDE Key - Results section should not include authors’ editorializing or offering interpretation of their data That is for the Discussion section of the manuscript Results section should be comprehensive of most relevant data but also concise Should not read like a “laundry list”

MANUSCRIPT TABLES: KEY POINTS “Readability” Too much/too little data provided to easily read Do the numbers in the table add-up? Confirm that no conflicting data (number discrepancies) between tables and text of results

Before After Spread over two pages

2. Appearance & detail Table 4

  Risk score <2 Risk score >2 (n=689, 66%) Overall (n=689) No radiotherapy (n=399, 58%) Radiotherapy (n=290, 42%) p value Overall (n=689) Age Mean (range%) 65.3 (40.5-83.4%) 65.6 (40.5-83.4%) 64.7 (41.1-79.6%) 0.09 PSA (ng/ml%) 12.6 (0.6-417.0%) 11.1 (0.6-417.0%) 14.9 (1.6-113.0%) 0.02 Gleason score ≤ 3+3=6 634 (93.3%) 380 (77.7%) 212 (73.1%) <0.001 3+4=7 145 (21.3%) 234 (54.1%) 121 (21.1%) 4+3=7 89 (12.3%) ≥ 8 80 (10.0%) Pathological stage pT2 580 (87.1%) 231 (57.9%) 135 (46.6%) pT3a 323 (46.9%) 168 (42.1%) 155 (53.4%) pT3b 109 (15.8%) 37 (9.3%) 72 (24.8%) pT4 1 (0.2%) 1 (0.1%) 0 (0%) Lymph node status pN0 612 (88.8%) 353 (88.5%) 259 (89.3%) 0.8 pN1 77 (11.2%) 46 (11.5%) 31 (10.7%) Surgical margin Negative 271 (39.3%) 149 (37.3%) 122 (42.1%) 0.2 Positive 418 (60.7%) 250 (62.7%) 168 (57.9%) Adjuvant therapy status None 399 (57.9%) 399 (100%) Radiotherapy only 290 (42.1%) 290 (100%) Radiotherapy & ADT 137 (19.9%) 53 (13.3%) 84 (29.0%) ADT only 552 (80.1%) 346 (86.7%) 206 (71.1%) Risk factors 1 2 3 * ADT = Androgen derpivation therapy Data are stratified according to the novel risk score and adjuvant radiotherapy status. Risk score derived from the sum of each risk factor (ie, pathologic Gleason score >8, pathologic stage pT3b/T4, and lymph node invasion) shared by each single patient

MANUSCRIPT TABLES: KEY POINTS Sequence/completeness of tables Demographic data – Table 1 +/- Univariable comparisons – Table 2 Often not provided, and that is ok Multivariable models – Tables 3+ HR, 95% CI, p values provided

TABLES: INCLUSIVE OF HR, 95% CI, p value

MANUSCRIPT FIGURES Make sure all the figures included are necessary No duplication with tables No present the obvious (i.e. CT image of renal mass biopsy) Is data presentation clear and not mis-labeled? Appropriate axis/scales on graphs Can figures be read “stand-alone” (without accompanying text)? For Kaplan-Meier curve: p values provided Number of patients at risk at various timepoints provided

p value Number at risk

CAPITALS No capitals What is this line doing here? No p value Where is the fourth line (Arm A, Censored) ? p value in a different place No p value

Midpoint Arm A Allocated (n=51) Received treatment (n=51) Did not receive treatment (n=0) Arm B Allocated (n=50) Received treatment (n=50) Did not receive treatment (n=0)

MANUSCRIPT FIGURES Randomized trial  CONSORT diagram = Figure 1 Systematic review/meta-analysis  diagram showing inclusion/exclusion criteria for studies Kaplan Meier analyses If presenting nomogram/statistical model  calibration curve

RESULTS SECTION OF THE ABSTRACT Key: Results section of the Abstract should be able to STAND ALONE For the casual reader who only reads the Abstract of the manuscript

RESULTS SECTION OF THE ABSTRACT: WHAT TO INCLUDE Number of patients included for study Critical demographic feature (pending word count) Duration of follow-up Number of events (i.e. deaths) – if possible within word count limits Kaplan Meier and multivariable results KM with p values (i.e. not just %) For multivariable analysis, HR with either 95% CI and/or p value (ideally all 3)

SAMPLE ABSTRACT WITH CRITICAL DATAPOINTS INCLUDED

HOW TO WRITE THE RESULTS SECTION: SUMMARY Move from broad to specific in text Demographicstreatmentoutcomes Provide median follow-up + specific number of events! Comprehensive but concise Avoid duplication of data in tables/figures

HOW TO WRITE THE RESULTS SECTION: SUMMARY Tables/Figures Follow logical sequence All are referenced in and consistent with text Key = ease of “readability”/interpretation Results section of the Abstract Provide critical demographic/outcome details such that can be read as “stand alone”

THANK YOU Questions?